HC Wainwright Comments on Evotec’s Q3 Earnings (NASDAQ:EVO)

Evotec AG (NASDAQ:EVO) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Evotec in a research note issued to investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.04) per share for the quarter, down from their previous forecast of ($0.01). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.31) EPS and FY2027 earnings at $0.07 EPS.

A number of other equities research analysts have also commented on the stock. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research report on Wednesday. Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Weiss Ratings upgraded shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.00.

Evotec Stock Performance

NASDAQ:EVO opened at $1.96 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. Evotec has a fifty-two week low of $1.95 and a fifty-two week high of $4.42. The company has a 50 day simple moving average of $2.75 and a two-hundred day simple moving average of $3.01.

Institutional Trading of Evotec

Several large investors have recently modified their holdings of EVO. Optiver Holding B.V. increased its stake in shares of Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after acquiring an additional 242,973 shares in the last quarter. WCM Investment Management LLC boosted its stake in Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after acquiring an additional 67,917 shares in the last quarter. Apollon Wealth Management LLC bought a new position in Evotec during the first quarter worth $28,000. SmartHarvest Portfolios LLC acquired a new stake in Evotec in the first quarter worth $44,000. Finally, XTX Topco Ltd grew its holdings in Evotec by 25.1% in the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company’s stock worth $57,000 after purchasing an additional 3,709 shares during the period. Institutional investors and hedge funds own 5.81% of the company’s stock.

Key Evotec News

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.